These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 27988109)

  • 81. Receptor Tyrosine Kinases as Therapeutic Targets for Alcohol Use Disorder.
    Hamada K; Lasek AW
    Neurotherapeutics; 2020 Jan; 17(1):4-16. PubMed ID: 31617071
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Oncogenic kinase fusions: an evolving arena with innovative clinical opportunities.
    Tabbò F; Pizzi M; Kyriakides PW; Ruggeri B; Inghirami G
    Oncotarget; 2016 May; 7(18):25064-86. PubMed ID: 26943776
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Novel tyrosine kinase signaling pathways: implications in vascular remodeling.
    Batchu SN; Korshunov VA
    Curr Opin Nephrol Hypertens; 2012 Mar; 21(2):122-7. PubMed ID: 22240445
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Receptor tyrosine kinases as therapeutic targets in malignant glioma.
    Ren H; Yang BF; Rainov NG
    Rev Recent Clin Trials; 2007 May; 2(2):87-101. PubMed ID: 18473993
    [TBL] [Abstract][Full Text] [Related]  

  • 85. A RTK-based functional RNAi screen reveals determinants of PTX-3 expression.
    Liu H; Qu XK; Yuan F; Zhang M; Fang WY
    Int J Clin Exp Pathol; 2013; 6(4):660-8. PubMed ID: 23573312
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Epigenetic regulation of RTK signaling.
    Spangle JM; Roberts TM
    J Mol Med (Berl); 2017 Aug; 95(8):791-798. PubMed ID: 28589435
    [TBL] [Abstract][Full Text] [Related]  

  • 87. The sum is greater than the FGFR1 partner.
    Braun BS; Shannon K
    Cancer Cell; 2004 Mar; 5(3):203-4. PubMed ID: 15050910
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Relationships between DNA repair and RTK-mediated signaling pathways.
    Chabot T; Cheraud Y; Fleury F
    Biochim Biophys Acta Rev Cancer; 2021 Jan; 1875(1):188495. PubMed ID: 33346130
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Expression, regulation and targeting of receptor tyrosine kinases in esophageal squamous cell carcinoma.
    Kashyap MK; Abdel-Rahman O
    Mol Cancer; 2018 Feb; 17(1):54. PubMed ID: 29455652
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Interactions between cholinergic and fibroblast growth factor receptors in brain trophism and plasticity.
    Di Liberto V; Mudo G; Fuxe K; Belluardo N
    Curr Protein Pept Sci; 2014; 15(7):691-702. PubMed ID: 25175454
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Kinase-mediated RAS signaling via membraneless cytoplasmic protein granules.
    Tulpule A; Guan J; Neel DS; Allegakoen HR; Lin YP; Brown D; Chou YT; Heslin A; Chatterjee N; Perati S; Menon S; Nguyen TA; Debnath J; Ramirez AD; Shi X; Yang B; Feng S; Makhija S; Huang B; Bivona TG
    Cell; 2021 May; 184(10):2649-2664.e18. PubMed ID: 33848463
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Chromosomal translocations in cancer and their relevance for therapy.
    Taki T; Taniwaki M
    Curr Opin Oncol; 2006 Jan; 18(1):62-8. PubMed ID: 16357566
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Kinase impact assessment in the landscape of fusion genes that retain kinase domains: a pan-cancer study.
    Kim P; Jia P; Zhao Z
    Brief Bioinform; 2018 May; 19(3):450-460. PubMed ID: 28013235
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Physical and functional interactome atlas of human receptor tyrosine kinases.
    Salokas K; Liu X; Öhman T; Chowdhury I; Gawriyski L; Keskitalo S; Varjosalo M
    EMBO Rep; 2022 Jun; 23(6):e54041. PubMed ID: 35384245
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Fibroblast Growth Factor Receptor (FGFR) Signaling in GIST and Soft Tissue Sarcomas.
    Napolitano A; Ostler AE; Jones RL; Huang PH
    Cells; 2021 Jun; 10(6):. PubMed ID: 34204560
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Mechanisms of rapid cancer cell reprogramming initiated by targeted receptor tyrosine kinase inhibitors and inherent therapeutic vulnerabilities.
    Kleczko EK; Heasley LE
    Mol Cancer; 2018 Feb; 17(1):60. PubMed ID: 29458371
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Phosphoproteomic studies of receptor tyrosine kinases: future perspectives.
    Huang PH
    Mol Biosyst; 2012 Apr; 8(4):1100-7. PubMed ID: 22134727
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Quantifying the strength of heterointeractions among receptor tyrosine kinases from different subfamilies: Implications for cell signaling.
    Paul MD; Grubb HN; Hristova K
    J Biol Chem; 2020 Jul; 295(29):9917-9933. PubMed ID: 32467228
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Feedback regulation of RTK signaling in development.
    Neben CL; Lo M; Jura N; Klein OD
    Dev Biol; 2019 Mar; 447(1):71-89. PubMed ID: 29079424
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Identification of metabolic vulnerabilities of receptor tyrosine kinases-driven cancer.
    Jin N; Bi A; Lan X; Xu J; Wang X; Liu Y; Wang T; Tang S; Zeng H; Chen Z; Tan M; Ai J; Xie H; Zhang T; Liu D; Huang R; Song Y; Leung EL; Yao X; Ding J; Geng M; Lin SH; Huang M
    Nat Commun; 2019 Jun; 10(1):2701. PubMed ID: 31221965
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.